Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00638547 · ClinicalTrials.gov registry record · Phase 1
Intrathecal Enzyme Replacement for Hurler Syndrome
A Phase 1 study of Hurler Syndrome, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT00638547: Completed Phase 1 study of Hurler Syndrome, sponsored by Masonic Cancer Center, University of Minnesota.
NCT00638547 is a Phase 1 study of Hurler Syndrome that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 26 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00638547, a Phase 1 study of Hurler Syndrome, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This protocol will examine whether the enzyme alpha-L-iduronidase (Laronidase), delivered into the spinal fluid of patients with Hurler syndrome at intervals before and after bone marrow transplant, is a safe and effective approach to slow the neurologic degeneration seen in Hurler patients undergoing transplantation.
Conditions Studied
Interventions
- DRUG IRT Laronidase
Study Locations (1)
Minnesota
- University of Minnesota, Fairview - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-01-02 |
| Est. Completion | 2018-11-18 |
| Phase | Phase 1 |
What the finished NCT00638547 record still lists
NCT00638547 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower).
The record links to 1 condition, with Hurler Syndrome appearing as the primary indexed condition, and to 1 intervention - of which IRT Laronidase is the first listed.
NCT00638547 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00638547 about?
NCT00638547 is a clinical study titled "Intrathecal Enzyme Replacement for Hurler Syndrome". This protocol will examine whether the enzyme alpha-L-iduronidase (Laronidase), delivered into the spinal fluid of patients with Hurler syndrome at intervals before and after bone marrow transplant, is a safe and effective approach to slow the neurologic degeneration seen in Hurler patients undergoi...
What is the current status of trial NCT00638547?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2008-01-02. Estimated completion is 2018-11-18.
What conditions does trial NCT00638547 study?
This clinical trial studies the following conditions: Hurler Syndrome.
What interventions are being tested in trial NCT00638547?
The interventions under investigation include: IRT Laronidase (DRUG).
Who is sponsoring clinical trial NCT00638547?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00638547 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hurler Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00638547's enrollment target sits among peer trials
26 1482nd of 2000 higher than 506 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI